马来酸曲美布汀联合埃索美拉唑治疗胃食管反流病患者的效果及安全性研究

Study on the efficacy and safety of Trimebutine Maleate combined with Esomeprazole in the treatment of patients with gastroesophageal reflux disease

目的探讨马来酸曲美布汀联合埃索美拉唑治疗胃食管反流病患者的临床效果及安全性。方法选取2019年8月至2020年8月广水市第二人民医院消化肾病内科收治的75例胃食管反流病患者作为研究对象,采用随机摸球法将其分为观察组(n=38)和对照组(n=37)。对照组采用埃索美拉唑治疗,观察组采用埃索美拉唑联合马来酸曲美布汀治疗。比较两组患者的临床疗效,比较两组患者治疗前后的食管远端平滑肌运动功能指标[食管远端收缩积分(DCI)、蠕动性收缩比例、下食管括约肌松弛率(LESRR)和食管下括约肌静息压(LESP)]、胃食管反流病健康相关生存质量量表(GERD-HRQL)评分及胃食管反流病诊断性症状评估量表(GerdQ)评分。结果观察组患者的治疗总有效率高于对照组,观察组患者治疗后的LESP、蠕动性收缩比例、LESRR、DCI均低于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后的GERD-HRQL各维度评分、GerdQ评分均低于对照组,差异有统计学意义(P<0.05)。两组患者治疗期间均未见不良反应。结论马来酸曲美布汀联合埃索美拉唑治疗胃食管反流病,能提高患者的治疗效果,改善患者食管下段平滑肌运动功能,提高患者生活质量,安全可靠。

Objective To investigate the clinical efficacy and safety of Trimebutine Maleate combined with Esomeprazole in the treatment of gastroesophageal reflux disease(GERD).Methods A total of 75 patients with gastroesophageal reflux disease admitted to the Department of Gastroenterology and Nephrology of the Second People's Hospital of Guangshui City from August 2019 to August 2020 were selected as the research subjects,and divided into observation group(n=38)and control group(n=37)by random touch ball method.The control group was treated with Esomeprazole,and the observation group was treated with Esomeprazole and Trammebutine Maleate.The clinical efficacy of the two groups was compared.The motor function indexes of distal esophageal smooth muscle(distal contraction integral[DCI],perperistaltic contraction ratio,lower esophageal sphincter relaxation ratio[LESRR]and low esophageal sphincter pressure[LESP]),gastroesophageal reflux disease health-related quality of life scale(GERD-HRQL)and gastroesophageal reflux disease quality scale(GerdQ)scores were compared between the two groups before and after treatment.Results The total effective rate of the observation group after treatment was higher than that of the control group,and the LESP,perperistaltic contraction ratio,LESRR and DCI of the observation group after treatment were all lower than those of the control group,with statistically significant differences(P<0.05).The GERD-HRQL scores of each dimension of the observation group after treatment were lower than those of the control group,and the GerdQ score of the observation group after treatment was lower than that of the control group,with statistically significant differences(P<0.05).There was no adverse reaction in the two groups during treatment.Conclusion Trimebutine Maleate combined with Esomeprazole can improve the therapeutic effect of patients with gastroesophageal reflux disease,improve the smooth muscle movement function of patients with lower esophagus,and improve the symptoms and quality of life of patients,which is safe and reliable.